CN108778266A - 包含二高γ亚麻酸（DGLA）的医药组合物和其用途 - Google Patents

包含二高γ亚麻酸（DGLA）的医药组合物和其用途 Download PDF

Info

Publication number
CN108778266A
CN108778266A CN201780015787.0A CN201780015787A CN108778266A CN 108778266 A CN108778266 A CN 108778266A CN 201780015787 A CN201780015787 A CN 201780015787A CN 108778266 A CN108778266 A CN 108778266A
Authority
CN
China
Prior art keywords
dgla
subject
disease
subjects
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780015787.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·邓恩
M·曼库
J·克莱麦克斯
D·考夫兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ds Biopharmaceutical Co ltd
Original Assignee
Ds Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ds Biopharmaceutical Co ltd filed Critical Ds Biopharmaceutical Co ltd
Publication of CN108778266A publication Critical patent/CN108778266A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780015787.0A 2016-01-07 2017-01-06 包含二高γ亚麻酸（DGLA）的医药组合物和其用途 Pending CN108778266A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276019P 2016-01-07 2016-01-07
US62/276,019 2016-01-07
US201662357000P 2016-06-30 2016-06-30
US62/357,000 2016-06-30
PCT/IB2017/000066 WO2017118911A1 (en) 2016-01-07 2017-01-06 Pharmaceutical compositions comprising dgla and use of same

Publications (1)

Publication Number Publication Date
CN108778266A true CN108778266A (zh) 2018-11-09

Family

ID=58213263

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780015787.0A Pending CN108778266A (zh) 2016-01-07 2017-01-06 包含二高γ亚麻酸（DGLA）的医药组合物和其用途

Country Status (6)

Country Link
US (2) US20170196825A1 (https=)
EP (1) EP3399971A1 (https=)
JP (1) JP2019501190A (https=)
CN (1) CN108778266A (https=)
CA (1) CA3027867A1 (https=)
WO (1) WO2017118911A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
ES2784240T3 (es) 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3624787A1 (en) * 2017-05-19 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
US10639313B2 (en) 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681896A (en) * 1983-02-01 1987-07-21 Efamol Limited Pharmaceutical and dietary composition
CN101019853A (zh) * 2005-02-14 2007-08-22 三得利株式会社 含有有效成分二均－γ－亚麻酸(DGLA)的组成物
WO2015185698A1 (en) * 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085687A1 (ja) * 2005-02-14 2006-08-17 Suntory Limited ジホモ−γ−リノレン酸（ＤＧＬＡ）を有効成分として含んで成る組成物
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681896A (en) * 1983-02-01 1987-07-21 Efamol Limited Pharmaceutical and dietary composition
CN101019853A (zh) * 2005-02-14 2007-08-22 三得利株式会社 含有有效成分二均－γ－亚麻酸(DGLA)的组成物
WO2015185698A1 (en) * 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Also Published As

Publication number Publication date
CA3027867A1 (en) 2017-07-13
US20170196825A1 (en) 2017-07-13
JP2019501190A (ja) 2019-01-17
WO2017118911A1 (en) 2017-07-13
US20190175534A1 (en) 2019-06-13
EP3399971A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
US11478442B2 (en) Pharmaceutical compositions comprising DGLA and use of same
CN108778266A (zh) 包含二高γ亚麻酸（DGLA）的医药组合物和其用途
CN111840269A (zh) 在接受抑制素治疗的受试者中降低心血管事件风险的方法
KR20200054171A (ko) 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법
CN113164377A (zh) 用于治疗炎性、纤维化和增生性病状的dgla和/或15-hetre
US20180333382A1 (en) Pharmaceutical compositions comprising dgla and use of same
HK40034640A (en) Pharmaceutical compositions comprising dgla and use of same
HK1236390B (en) Pharmaceutical compositions comprising dgla and use of same
HK1236390A1 (en) Pharmaceutical compositions comprising dgla and use of same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181109